Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: A PET study in conscious monkeys

Neuropsychopharmacology

Volumn 38, Issue 13, 2013, Pages 2666-2674

  Yamamoto, Shigeyuki ^a   Ohba, Hiroyuki ^a   Nishiyama, Shingo ^a   Harada, Norihiro ^a   Kakiuchi, Takeharu ^a   Tsukada, Hideo ^a   Domino, Edward F ^b  

^a Central Research Laboratory   (Japan)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

11C DASB; monkey; PET; serotonin transporer; subanesthetic ketamine

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYL PHENYLSULFANYL)BENZONITRILE C 11; DOPAMINE TRANSPORTER; KETAMINE; RADIOISOTOPE; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; EXTRACELLULAR FLUID; MALE; MICRODIALYSIS; NEUROBIOLOGY; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RHESUS MONKEY; SEROTONERGIC TRANSMISSION; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; BENZYLAMINES; BRAIN; CARBON ISOTOPES; COCAINE; CONSCIOUSNESS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORODEOXYGLUCOSE F18; IMAGE PROCESSING, COMPUTER-ASSISTED; KETAMINE; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MICRODIALYSIS; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84887995677     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.176     Document Type: Article

References (75)

1. 2 receptor binding in man. Psychopharmacology 164: 401-406.
2. Artigas F (1993). 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 14: 262.
3. Artigas F, Perez V, Alvarez E (1994). Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 248-251.
4. Bel N, Artigas F (1992). Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 229: 101-103.
5. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al(2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354.
6. Beyer CE, Boikess S, Luo B, Dawson LA (2002). Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 16: 297-304.
7. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L et al(1998). Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29: 142-147.
8. 1A receptors. Br J Pharmacol 142: 469-478.
9. 2A receptors in depression. J Psychiatry Neurosci 29: 252-265.
10. Chaput Y, de Montigny C, Blier P (1986). Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 333: 342-348.
11. Clements JA, Nimmo WS, Grant IS (1982). Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 71: 539-542.
12. 1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol 345: 41-46.
13. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S et al(2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793-802.
14. Domino EF, Chodoff P, Corssen G (1965). Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 6: 279-291.
15. Feng J, Cai X, Zhao J, Yan Z (2001). Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J Neurosci 21: 6502-6511.
16. Frazer A (1997). Pharmacology of antidepressants. J Clin Psychopharmacol (1997; 17(Suppl 1): 2S-18S.
17. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115: 1064-1070.
18. 18F]fluoro-ethyl)nortropane) as a dopamine transporter ligand: a PET study in the conscious monkey brain. Synapse 54: 37-45.
19. Hartvig P, Valtysson J, Antoni G, Westerberg G, Långström B, Ratti Moberg E et al(1994). Brain kinetics of (R)-and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET). Nucl Med Biol 21: 927-934.
20. 1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neurophar-macology 36: 461-465.
21. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al(2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
22. Invernizzi R, Belli S, Samanin R (1992). Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584: 322-324.
23. 1A receptors. Eur J Pharmacol 260: 243-246.
24. 1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol Biochem Behav 54: 143-147.
25. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O et al(2002). NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43: 19-29.
26. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al(2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
27. Kia HK, Brisorgueil MJ, Hamon M, Calas A, Vergé D (1996a). Ultrastructural localization of 5-hydroxytryptamine1A receptors in the rat brain. J Neurosci Res 46: 697-708.
28. Kia HK, Miquel MC, Brisorgueil MJ, Daval G, Riad M, El Mestikawy S et al(1996b). Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J Comp Neurol 365: 289-305.
29. Krystal JH (2010). N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants. Arch Gen Psychiatry 67: 1110-1111.
30. 11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy. Epilepsia 40: 30-37.
31. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al(2010). mTOR-dependent synapse formation underlies the rapid anti-depressant effects of NMDA antagonists. Science 329: 959-964.
32. Lindefors N, Barati S, O'Connor WT (1997). Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res 759: 205-212.
33. 11C-methyl]-(-)-co-caine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747.
34. López-Gil X, Babot Z, Amargós-Bosch M, Sunol C, Artigas F, Adell A (2007). Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharma-cology 32: 2087-2097.
35. Martin DC, Introna RP, Aronstam RS (1990). Inhibition of neuronal 5-HT uptake by ketamine, but not halothane, involves disruption of substrate recognition by the transporter. Neurosci Lett 112: 99-103.
36. 11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency. Biol Psychiatry 57: 102-106.
37. 11)C]DASB PET imaging study. Am J Psychiatry 158: 1843-1849.
38. 11C]DASB positron emission tomography study. Am J Psychiatry 161: 826-835.
39. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
40. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron 34: 13-25.
41. Nikiforuk A, Goembiowska K, Popik P (2010). Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol 20: 37-48.
42. Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S et al(1998). Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88: 768-774.
43. 2 receptors and response to methamphetamine challenge in monkey brain. Synapse 63: 534-537.
44. 11C-methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey. Brain Res 663: 191-198.
45. Osawa Y, Kanamori H, Seki E, Hoshi M, Ohtaki H, Yasuda Y et al (2011). L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin. J Biol Chem 286: 34800-34808.
46. Poleszak E, Wlaź P, Szewczyk B, Wlaź A, Kasperek R, Wróbel A et al(2011). A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm 118: 1535-1546.
47. Price RB, Nock MK, Charney DS, Mathew SJ (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66: 522-526.
48. Purkayastha S, Ford J, Kanjilal B, Diallo S, Del Rosario Inigo J, Neuwirth L et al(2012). Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions. J Neurochem 120: 396-407.
49. 11C][O-methyl- 3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexa-necarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther 301: 1144-1150.
50. Ramamoorthy S, Blakely RD (1999). Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285: 763-766.
51. Reich DL, Silvay G (1989). Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 36: 186-197.
52. 18F]MPPF in the nucleus raphe dorsalis of rat. J Neurosci 24: 5420-5426.
53. Salomon RM, Miller HL, Delgado PL, Charney D (1993). The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders. Int Clin Psychopharmacol Suppl 2: 41-46.
54. 18F-FE-PE2I. J Nucl Med 53: 1065-1073.
55. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol 121: 941-946.
56. 18F]MPPF binding potential in the dorsal raphe nucleus after a single oral dose of fluoxetine: a positron-emission tomography study in healthy volunteers. Neuroimage 63: 1135-1140.
57. 11C-raclopride in normal human subjects. Neuropsychopharma-cology 18: 18-25.
58. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F et al(2003). High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60: 386-391.
59. 11C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43: 678-692.
60. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al(2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
61. 1A receptors in the living monkey brain: a positron emission tomography study using microdialysis. J Cereb Blood Flow Metab 24: 898-906.
62. 11C]raclopride binding with no alteration in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: Multi-parametric PET studies combined with microdialysis analysis. Synapse 37: 95-103.
63. 11)C]b-CIT-FE in the monkey brain. Synapse 42: 273-280.
64. 18F]MPPF binding: a continuous infusion PET study in conscious monkeys. Synapse 59: 18-26.
65. Verma A, Moghaddam B (1996). NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16: 373-379.
66. Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T et al(1997). A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 44: 1277-1282.
67. Whitton PS, Biggs CS, Pearce BR, Fowler LJ (1992). MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J Neurochem 58: 1573-1575.
68. 11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 43: 3103-3110.
69. 11C]DASB to serotonin transporters in conscious monkey brain. Synapse 61: 724-731.
70. Yan QS, Reith ME, Jobe PC, Dailey JW (1997). Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephr-ine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 765: 149-158.
71. 11C]DASB in conscious common marmosets: comparison with rhesus monkeys. Synapse 64: 594-601.
72. 1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J Neurosci 25: 5488-5501.
73. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al(2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
74. Zhao Y, Sun L (2008). Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function. J Clin Neurosci 15: 1264-1269.
75. 1A autoreceptor internalization. Neuroimage 22: 1421-1426.